Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Tempescul

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Journal for Immunotherapy of Cancer|January 31, 2019
17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemiaCristina Bagacean, Adrian Tempescul, David Ternant, et al.
Oncotarget|September 1, 2018
Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapyAnne Bordron, Cristina Bagacean, Audrey Mohr, et al.
Oncoimmunology|February 7, 2019
The regulatory capacity of B cells directs the aggressiveness of CLLAudrey Mohr, Marie Cumin, Cristina Bagacean, et al.
Oncotarget|October 15, 2017
Alterations in DNA methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic leukemiaCristina Bagacean, Adrian Tempescul, Christelle Le Dantec, et al.
Haematologica|December 17, 2017
Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)Ronan Le Calloch, Karine Lacut, Christelle Le Gall-Ianotto, et al.
Journal for Immunotherapy of Cancer|April 25, 2019
STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemiaMarjolaine Debant, Miguel Burgos, Patrice Hemon, et al.
Annals of Hematology|July 16, 2025
Consequences and impacts of PEG-IFNα2a shortage: first lessons from a MPN French centerLaura Cailly, Wayne-Corentin Lambert, Jean-Richard Eveillard, et al.
Leukemia & Lymphoma|March 9, 2017
Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE studyDriss Chaoui, Sylvain Choquet, Laurence Sanhes, et al.
Journal of Leukocyte Biology|July 21, 2021
Identification of altered cell signaling pathways using proteomic profiling in stable and progressive chronic lymphocytic leukemiaCristina Bagacean, Cristina Adela Iuga, Anne Bordron, et al.
British Journal of Haematology|April 21, 2022
Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA)Guillaume Manson, Charles Herbaux, Jean-Marc Schiano, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Journal for Immunotherapy of Cancer|January 31, 2019
17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemiaCristina Bagacean, Adrian Tempescul, David Ternant, et al.
Oncotarget|September 1, 2018
Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapyAnne Bordron, Cristina Bagacean, Audrey Mohr, et al.
Oncoimmunology|February 7, 2019
The regulatory capacity of B cells directs the aggressiveness of CLLAudrey Mohr, Marie Cumin, Cristina Bagacean, et al.
Oncotarget|October 15, 2017
Alterations in DNA methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic leukemiaCristina Bagacean, Adrian Tempescul, Christelle Le Dantec, et al.
Haematologica|December 17, 2017
Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)Ronan Le Calloch, Karine Lacut, Christelle Le Gall-Ianotto, et al.
Journal for Immunotherapy of Cancer|April 25, 2019
STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemiaMarjolaine Debant, Miguel Burgos, Patrice Hemon, et al.
Annals of Hematology|July 16, 2025
Consequences and impacts of PEG-IFNα2a shortage: first lessons from a MPN French centerLaura Cailly, Wayne-Corentin Lambert, Jean-Richard Eveillard, et al.
Leukemia & Lymphoma|March 9, 2017
Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE studyDriss Chaoui, Sylvain Choquet, Laurence Sanhes, et al.
Journal of Leukocyte Biology|July 21, 2021
Identification of altered cell signaling pathways using proteomic profiling in stable and progressive chronic lymphocytic leukemiaCristina Bagacean, Cristina Adela Iuga, Anne Bordron, et al.
British Journal of Haematology|April 21, 2022
Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA)Guillaume Manson, Charles Herbaux, Jean-Marc Schiano, et al.
Pageof 7